Jeevan Scientific Technology Limited has announced a strategic acquisition of a 60% stake in M/s. Naya Pharma Private Limited for ₹10.00 crores, as disclosed in a regulatory filing under Regulation 30 of SEBI (LODR) Regulations, 2015. The acquisition represents a significant step in the company's diversification and expansion strategy into the pharmaceutical sector.

Acquisition Structure and Funding

The acquisition will be funded through proceeds raised from the preferential issue approved by shareholders in an Extraordinary General Meeting. The company had approved the issue and allotment of 35,00,000 convertible warrants to Promoters and Non-Promoters, along with 41,85,000 equity shares to Non-Promoters.

Target Company Profile

Naya Pharma Private Limited was incorporated on August 19, 2020, and operates in the pharmaceutical manufacturing sector. The company has a current paid-up capital of ₹3,66,70,330, divided into 36,67,033 equity shares of ₹10.00 each.

Business Operations and Synergies

Naya Pharma's business objects include manufacturing, production, buying, selling, importing, exporting, trading, and dealing in Active Pharmaceutical Ingredients (bulk drugs), Drug Intermediates, Organic and Inorganic chemicals, Fine Chemicals, and Dye Pigments both in India and abroad. This acquisition aligns with Jeevan Scientific's diversification strategy and creates synergy for the clinical trials business undertaken by the acquiring company.

Related Party Transaction Details

The acquisition qualifies as a related party transaction, as Mrs. Snigdha Mothukuri and Mrs. K. Vanaja are shareholders holding 100% shareholding in Naya Pharma. These individuals are also promoters of Jeevan Scientific Technology Limited. Additionally, Mr. K. Krishna Kishore and Mrs. Snigdha Mothukuri serve as common directors on the boards of both the investing and investee companies. Currently, Jeevan Scientific has three directors: Mr. K. Krishna Kishore, Mrs. Snigdha Mothukuri, and Mrs. K. Vanaja.

Regulatory Compliance

The company has confirmed that no governmental or regulatory approvals are required for this acquisition. The disclosure has been made in compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jeevan Scientific Technology Limited (JSTL) held a successful Extraordinary General Meeting (EGM) on November 12, 2025, where shareholders approved four significant resolutions, paving the way for potential growth and structural changes within the company.

Meeting Details

The EGM, conducted through video conferencing from 10:00 AM to 10:40 AM, saw the participation of 58 members out of a total of 5,436 shareholders on the record date. The meeting was chaired by Mr. Divakar Atluri, with key management personnel, including Managing Director K. Krishna Kishore and Company Secretary Krishna Sainadh Kodati, in attendance.

Approved Resolutions

The shareholders passed the following resolutions with the requisite majority:

1. Adoption of New Memorandum of Association: A special resolution to adopt a new Memorandum of Association in compliance with the Companies Act, 2013.

2. Increase in Authorized Share Capital: An ordinary resolution to increase the authorized share capital from Rs. 21 crore to Rs. 25 crore, divided into 2.5 crore equity shares of Rs. 10 each.

3. Issue of Convertible Warrants: A special resolution to approve the issuance of convertible warrants on a preferential basis to promoters and non-promoters for cash consideration.

4. Issue of Equity Shares: A special resolution to approve the issuance of equity shares on a preferential basis to non-promoters for cash consideration.

Voting Results

The voting process included remote e-voting from November 9-11, 2025, and electronic voting during the meeting. Here's a summary of the voting results:

Implications

These resolutions suggest that Jeevan Scientific Technology Limited may be preparing for expansion or significant corporate actions. The increase in authorized share capital and approval for issuing convertible warrants and equity shares could indicate plans for raising funds, potentially for growth initiatives or strengthening the company's financial position.

The adoption of a new Memorandum of Association aligns the company with the latest regulatory requirements, which may enhance corporate governance practices.

Investors and stakeholders will likely be watching closely to see how JSTL utilizes these approvals to drive future growth and create value for shareholders.

As the company moves forward with these resolutions, it will be crucial to monitor how effectively management implements these changes and the impact on JSTL's financial performance and market position in the coming quarters.